+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls



Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls



Journal of Infectious Diseases 170(6): 1424-1431



Sera from 133 cervical cancer patients and 154 healthy women (controls) from Spain and Colombia were tested in IgG-specific ELISAs for the presence of antibodies against seven peptides derived from five open-reading frames of human papillomavirus (HPV) type 16. Three of the peptides corresponded to overlapping regions of the N-terminal half of E7 protein; the other peptides corresponded to selected regions of E2, E4, L1, and L2 proteins. The prevalence of antibodies against E2 and E7 peptides was significantly different between patients and controls. The most marked differences were for E7 peptides. HPV DNA polymerase chain reaction diagnoses of cervical scrapes were available; these were correlated with serologic findings. In HPV-16 DNA-positive patients, E7 antibodies were more broadly and more strongly reactive than in other patient groups.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047054721

Download citation: RISBibTeXText

PMID: 7995981


Related references

Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Research 50(24): 7815-7819, 1990

Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku Journal of Experimental Medicine 170(2): 113-121, 1993

Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls. International Journal of Cancer 48(5): 682-688, 1991

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. Journal of Clinical Oncology 15(2): 610-619, 1997

Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. Journal of General Virology 78: 917-923, 1997

Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. Journal of Infectious Diseases 172(1): 19-24, 1995

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. Journal of Clinical Microbiology 29(8): 1579-1588, 1991

Presence Of Antibodies To Seven Human Papillomavirus Type 16-Derived. Journal of Infectious Diseases 170(6): 1424-1431, 1994

Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. Journal of Virology 81(6): 2869-2879, 2007

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clinical Cancer Research 14(1): 178-187, 2008

Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients. Archives of Virology 137(3-4): 341-353, 1994

A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo Journal 3(5): 1151-1157, 1984

Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer 74(8): 2307-2313, 1994

Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. Journal of Clinical Microbiology 34(12): 3056-3062, 1996

Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients. Fems Immunology and Medical Microbiology 54(2): 167-176, 2008